- Home
- ADAG vs PLX Comparison
ADAG vs PLX Comparison
Compare ADAG & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADAG | PLX |
|---|---|---|
| Founded | 2011 | 1993 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 260.3M | 182.9M |
| IPO Year | 2020 | 1996 |
Fundamental Metrics
Financial Performance| Metric | ADAG | PLX |
|---|---|---|
| Price | $3.35 | $2.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $8.25 | ★ $12.00 |
| AVG Volume (30 Days) | 204.3K | ★ 785.5K |
| Earning Date | 04-01-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.27 |
| Revenue | N/A | ★ $52,744,000.00 |
| Revenue This Year | N/A | $36.81 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.81 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.44 | $1.60 |
| 52 Week High | $4.85 | $3.19 |
Technical Indicators
Market Signals| Indicator | ADAG | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 45.92 | 65.31 |
| Support Level | $3.49 | $2.59 |
| Resistance Level | $4.25 | $2.71 |
| Average True Range (ATR) | 0.20 | 0.08 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 29.00 | 100.00 |
Price Performance
Historical ComparisonAbout ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.